Table 4 Antidiabetic drug use, by trimester, in livebirth pregnancies among women with pre-existing diabetes during 2001–2013 in the MSDD
|  | Use in the 90 Days Before Pregnancy | Any Use During Pregnancy | Any Use, First Trimester | Any Use, Second Trimester | Any Use, Third Trimester |
|---|---|---|---|---|---|
Total unique pregnancies | 15,606 (100%) | 15,606 (100%) | 15,606 (100%) | 15,606 (100%) | 15,594 (100%) |
Drug Product/Class | |||||
 Use of Any Drug | 13,847 (88.7%) | 14,488 (92.8%) | 13,322 (85.4%) | 12,876 (82.5%) | 12,998 (83.4%) |
 Metformin | 6024 (38.6%) | 5886 (37.7%) | 5572 (35.7%) | 3533 (22.6%) | 2257 (14.5%) |
 Sulfonylureas – Any Drug | 2018 (12.9%) | 2803 (18.0%) | 1916 (12.3%) | 1532 (9.8%) | 1414 (9.1%) |
  Glipizide | 675 (4.3%) | 596 (3.8%) | 573 (3.7%) | 270 (1.7%) | 91 (0.6%) |
  Glyburide | 976 (6.3%) | 2001 (12.8%) | 1097 (7.0%) | 1162 (7.5%) | 1268 (8.1%) |
 Thiazolidinediones | 965 (6.2%) | 800 (5.1%) | 786 (5.0%) | 258 (1.7%) | 104 (0.7%) |
 Combination Products | 565 (3.6%) | 502 (3.2%) | 480 (3.1%) | 166 (1.1%) | 73 (0.5%) |
 Insulin | 7351 (47.1%) | 11,796 (75.6%) | 9625 (61.7%) | 10,776 (69.1%) | 11,328 (72.6%) |